Longeveron (LGVN) Non-Current Assets (2021 - 2026)
Longeveron (LGVN) recorded quarterly Non-Current Assets of $4.4 million in Q1 2026, down 9.46% quarter-over-quarter from $4.8 million in Q4 2025, and down 21.86% on a YoY basis from $5.6 million in Q1 2025.
Longeveron (LGVN) Non-Current Assets (2021 - 2026) Analysis & Trends
Longeveron's Non-Current Assets history runs 6 years deep, the most recent figure standing at $4.4 million for Q1 2026.
- In Q1 2026, Non-Current Assets fell 21.86% year-over-year to $4.4 million; the TTM figure through Mar 2026 stood at $19.9 million (down 15.95% YoY), while the FY2025 annual figure was $4.8 million, down 18.94% from the prior year.
- Non-Current Assets was $4.4 million for Q1 2026 at Longeveron, down from $4.8 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $7.1 million in Q4 2022 to a low of $4.4 million in Q1 2026.
- Historically, Non-Current Assets has averaged $5.9 million across 5 years, with a median of $6.0 million in 2024.
- The sharpest annual moves came in 2022 and 2026: Non-Current Assets retreated 3.43% in 2022, then dropped 21.86% in 2026.
- A 5-year view of Non-Current Assets shows it stood at $7.1 million in 2022, then dropped by 12.66% to $6.2 million in 2023, then dropped by 4.75% to $5.9 million in 2024, then dropped by 18.94% to $4.8 million in 2025, then slipped by 9.46% to $4.4 million in 2026.
- The last three Non-Current Assets figures came in at $4.4 million (Q1 2026), $4.8 million (Q4 2025), and $5.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 62,953.78 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 289.41 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 4.56 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 486.60 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 30.30 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 5.18 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 14.75 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 39.71 Mn |
| 10 | Longeveron | 20.35 Bn | 20.33 Bn | 264,000.00 | 4.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.36 Mn |
| Dec 31, 2025 | 4.81 Mn |
| Sep 30, 2025 | 5.22 Mn |
| Jun 30, 2025 | 5.48 Mn |
| Mar 31, 2025 | 5.57 Mn |
| Dec 31, 2024 | 5.93 Mn |
| Sep 30, 2024 | 6.14 Mn |
| Jun 30, 2024 | 5.98 Mn |
| Mar 31, 2024 | 5.94 Mn |
| Dec 31, 2023 | 6.23 Mn |
| Sep 30, 2023 | 6.58 Mn |
| Jun 30, 2023 | 6.80 Mn |
| Mar 31, 2023 | 6.94 Mn |
| Dec 31, 2022 | 7.13 Mn |
| Dec 31, 2021 | 7.39 Mn |